Ticker

Individual experimental treatment attempt at Hopp Children's Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TCR T-cell therapy engineered with a PRAME-directed TCR provided by Immatics 17-year-old adolescent with bulky, rapidly progressing nephroblastoma and no remaining treatment options achieved deep remission, including marked regression of liver, lung and brain metastases;…

SG Americas Securities LLC acquired a new stake in shares of Immatics N.V. (NASDAQ: IMTX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 208,456 shares of the company's stock, valued at approximately $2,189,000. SG Americas Securities LLC owned

Shares of Immatics N.V. (NASDAQ: IMTX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have issued a buy recommendation on the company.

Immatics (IMTX) remains a speculative Buy, driven by progress with anzu-cel in 2L melanoma and a robust cell therapy pipeline. IMTX's valuation reflects high expectations, with the PRAME franchise and next-generation assets like IMA402 representing key upside optionality. SUPRAME's mid-2026 interim update is a pivotal go/no-go catalyst, but unlikely to deliver a near-term stock-moving data readout.

Immatics N.V. (NASDAQ: IMTX - Get Free Report)'s share price traded down 5% on Friday. The stock traded as low as $9.95 and last traded at $9.79. 25,593 shares were traded during trading, a decline of 93% from the average session volume of 381,668 shares. The stock had previously closed at $10.30. Wall Street Analysts